# A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects

> **NCT07571824** · PHASE1 · RECRUITING · sponsor: **Corium Innovations, Inc.** · enrollment: 92 (estimated)

## Conditions studied

- Healthy Adult Participants

## Interventions

- **DRUG:** Selegiline TDS 6 mg/24 hours
- **DRUG:** EMSAM® TDS 6 mg/24 hours

## Key facts

- **NCT ID:** NCT07571824
- **Lead sponsor:** Corium Innovations, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-23
- **Primary completion:** 2026-06-29
- **Final completion:** 2026-07-29
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07571824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07571824, "A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT07571824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*